S
Stephan Rössner
Researcher at Apple Inc.
Publications - 174
Citations - 12489
Stephan Rössner is an academic researcher from Apple Inc.. The author has contributed to research in topics: Weight loss & Body mass index. The author has an hindex of 53, co-authored 174 publications receiving 11820 citations. Previous affiliations of Stephan Rössner include Luton and Dunstable Hospital & Karolinska University Hospital.
Papers
More filters
Journal ArticleDOI
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
TL;DR: CB1 blockade with rimonabant 20 mg, combined with a hypocaloric diet over 1 year, promoted significant decrease of bodyweight and waist circumference, and improvement in cardiovascular risk factors.
Journal ArticleDOI
Who succeeds in maintaining weight loss? A conceptual review of factors associated with weight loss maintenance and weight regain.
K Elfhag,Stephan Rössner +1 more
TL;DR: Successful weight maintenance is associated with more initial weight loss, reaching a self‐determined goal weight, having a physically active lifestyle, a regular meal rhythm including breakfast and healthier eating, control of over‐eating and self‐monitoring of behaviours.
Journal ArticleDOI
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
Arne Astrup,Stephan Rössner,Luc Van Gaal,Aila Rissanen,Leo Niskanen,Mazin Al Hakim,Jesper J. Madsen,MF Rasmussen,Michael E. J. Lean +8 more
TL;DR: Liraglutide treatment over 20 weeks is well tolerated, induces weight loss, improves certain obesity-related risk factors, and reduces prediabetes.
Journal ArticleDOI
Effect of sibutramine on weight maintenance after weight loss: a randomised trial
W. Philip T. James,Arne Astrup,Nick Finer,Jannik Hilsted,Peter Kopelman,Stephan Rössner,Wim H. M. Saris,Luc Van Gaal +7 more
TL;DR: Changes in concentrations of HDL cholesterol, VLDL cholesterol, and triglyceride, but not LDL cholesterol, exceed those expected either from weight loss alone or when induced by other selective therapies for low concentrations of LDL cholesterol relating to coronary heart disease.
Journal ArticleDOI
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.
Arne Astrup,R Carraro,Nick Finer,A Harper,Marie Kunešová,Michael E. J. Lean,Leo Niskanen,MF Rasmussen,Aila Rissanen,Stephan Rössner,Markku J. Savolainen,L. Van Gaal +11 more
TL;DR: Liraglutide is well tolerated, sustains weight loss over 2 years and improves cardiovascular risk factors.